IJT - CIR - February 2024 - 63S

Cherian et al.
63S
rare-serious-risk-heart-attack-and-death-cardiac-nuclear-stress-testdrugs-lexiscan.
Accessed May 17, 2019.
22. Astellas Pharma US I. ADENOSCAN® (adenosine injection)
for intravenous infusion only. 2013. Last Updated.
https://www.accessdata.fda.gov/drugsatfda_docs/label/
2014/020059s016lbl.pdf. Accessed August 6, 2019.
23. Alencar A, Montes G, Barreiro E, Sudo R, Zapata-Sudo G.
Adenosine receptors as drug targets for treatment of pulmonary
arterial hypertension. Front Pharmacol. 2017;8:858.
24. Hayashida M, Fukuda K, Fukunaga A. Clinical application of
adenosine and ATP for pain control. J Anesth. 2005;19(3):
225-235.
25. Sherlock C, Corey L. Adenosine monophosphate for the
treatment of varicella zoster infections: a large dose of caution.
JAMA. 1985;253(10):1444-1445.
26. Sklar S, Blue W, Alexander E, Bodian CA. Herpes zoster. The
treatment and prevention of neuralgia with adenosine monophosphate.
JAMA. 1985;253(10):1427-1430.
27. Gajados A. Letter: A.M.P. in Porphyria cutanea tarda. Lancet.
1974;1(7849):163.
28. Agteresch H, Dagnelie P, van den Berg JW, Wilson J. Adenosine
triphosphate: established and potential clinical applications.
Drugs. 1999;58(2):211-232.
29. Agteresch H, Dagnelie P, van der Gaast A, Stijnen T, Wilson J.
Randomized clinical trial of adenosine 50-triphosphate in patients
with advanced non-small-cell lung cancer. JNatl Cancer
Inst. 2000;92(4):321-328.
30. Arts I, Coolen E, Bours M, et al. Adenosine 50-triphosphate
(ATP) supplements are not orally bioavailable: a randomized,
placebo-controlled cross-over trial in healthy humans. JInt Soc
Sports Nutr. 2012;9(1):16.
31. Kadir R, Stempler D, Liron Z, Cohen S. Penetration of adenosine
into excised human skin from binary vehicles: the enhancement
factor. J Pharmaceut Sci. 1988;77(5):409-413.
32. Malmary-Nebot M, Oustrin J, Gauci M. The fate of adenosine
monophosphate in the rat after a single oral administration.
Influence ofa simultaneous treatment by papaverine. EurJDrug
Metab Pharmacokinet. 1979;4(2):97-101.
33. Norwegian Food Safety Authority. Risk profile adenosine. 2012.
https://www.mattilsynet.no/kosmetikk/stoffer_i_kosmetikk/
risk_profile_adenosine.9866/binary/Risk_Profile_Adenosine.
Accessed May 20, 2019.
34. Cheng F, Li W, Zhou Y, et al. admetSAR: a comprehensive
source and free tool for assessment of chemical ADMET
properties. J Chem InfModel. 2012;52(11):3099-3105.
35. Kichenin K, Decollogne S, Angignard J, Seman M. Cardiovascular
and pulmonary response to oral administration ofATP
in rabbits. J Appl Physiol. 2000;88(6):1962-1968.
36. U.S. National Library of Medicine (NLM). ChemIDplus: adenosine
triphosphate disodium. Last Updated: 2020 https://chem.nlm.
nih.gov/chemidplus/rn/987-65-5. Accessed February 14, 2020.
37. McCartney M, McCoy E, Rosenkranz H, Giner-Sorolla A.
Carcinogenic N-hydroxylaminopurine derivatives do not act as
base analog mutagens in Salmonella typhimurium. Mutat Res.
1985;144:231-237.
38. Guzzie P, Oshiro Y, Soelter S, et al. Selection and evaluation ofan
appropriate model for screening adenosine analogs for chromosomal
aberrations. Toxicol Mech Methods. 1991;1(3):127-187.
39. Ishii K, Green H. Lethality ofadenosine for cultured mammalian
cells by interference with pyrimidine biosynthesis. J Cell Sci.
1973;13(2):429-439.
40. Mujoomdar M, Hoskin D, Blay J. Adenosine stimulation of the
proliferation of colorectal carcinoma cell lines; roles of cell
density and adenosine metabolism. Biochem Pharmacol. 2003;
66(9):1737-1747.
41. Hagermark O, Diamant B, Dahlquist R. Release of histamine
from human skin induced by intracutaneous injection of adenosine-50-triphosphate.
Int Arch Allergy. 1974;47(2):167-174.
42. Coutts A, Jorizzo J, Eady RA, Greaves M, Burnstock G.
Adenosine triphosphate-evoked vascular changes in human skin:
mechanism of action. Eur J Pharmacol. 1981;76(4):391-401.
43. Anonymous. Summaries of studies on adenosine. 2019. (Unpublished
data submitted by the Personal Care Products Council
on August 2, 2019).
44. Anonymous. Summary of studies of a trade name mixture
containing: 15% mannitol and 15% disodium adenosine Triphosphate.
2019. (Unpublished data submitted by the Personal
Care Products Council on June 19, 2019).
45. Cushley M, Holgate S. Adenosine-induced bronchoconstriction
in asthma: role of mast cell-mediator release. J Allergy Clin
Immunol. 1985;75(2):272-278.
46. BasogluO,PellegA,Essilfie-Quaye S, Brindicci C, Barnes P,
Kharitonov S. Effects of aerosolized adenosine 50-triphosphate vs
adenosine 50-monophosphate on dyspnea and airway caliber in healthy
nonsmokers and patients with asthma. Chest. 2005;128(4):1905-1909.
47. Fowles H, Rowland T, Wright C, Morice A. Tussive challenge
with ATP and AMP: does it reveal cough hypersensitivity? Eur
Respir J. 2017;49(2):1601452.
48. Wilson JM, Joy JM, Lowery RP, et al. Effects oforal adenosine50-triphosphate
supplementation on athletic performance,
skeletal muscle hypertrophy and recovery in resistance-trained
men. Nutr Metab. 2013;10(57):57.
49. Physicians' Desk Reference. 63rd ed. Montvale, NJ: Thomson
Health Care Inc; 2009:102.
50. Lewis R. Adenosine. Hawley's Condensed Chemical Dictionary.
15th ed. New York, NY: John Wiley and Sons, Inc; 2007:24.
51. ChemDraw Pro. 13.0. Waltham, MA: PerkinElmer Inc; 2019.
52. U.S. Environmental Protection Agency (EPA). Estimation
Program Interface (EPI) Suite. Ver. 4.0. 2009.
53. Lide D. CRC Handbook of Chemistry and Physics. 88th ed.
Boca Raton, FL: CRC Press, Taylor and Francis; 2007:3-87.
54. Human Metabolome Database (HMBD). Metabocard for adenosine
monophosphate (HMDB0000045). 2019. https://www.
hmdb.ca/metabolites/HMDB0000045. Accessed May 23, 2019.
55. ALOGPS 2.1 virtual computational chemistry laboratory. 2019.
56. Human Metabolome Database (HMBD). Metabocard for
adenosine triphosphate (HMDB0000538). https://www.hmdb.
ca/metabolites/HMDB0000538. Accessed May 23, 2019.
57. Royal Society of Chemistry. Adenosine triphosphate M1413.
The Merck Index. 12th ed.; 1996.
https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-rare-serious-risk-heart-attack-and-death-cardiac-nuclear-stress-test-drugs-lexiscan https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-rare-serious-risk-heart-attack-and-death-cardiac-nuclear-stress-test-drugs-lexiscan https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020059s016lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020059s016lbl.pdf https://www.mattilsynet.no/kosmetikk/stoffer_i_kosmetikk/risk_profile_adenosine.9866/binary/Risk_Profile_Adenosine https://www.mattilsynet.no/kosmetikk/stoffer_i_kosmetikk/risk_profile_adenosine.9866/binary/Risk_Profile_Adenosine https://www.hmdb.ca/metabolites/HMDB0000045 https://www.hmdb.ca/metabolites/HMDB0000045 https://chem.nlm.nih.gov/chemidplus/rn/987-65-5 https://chem.nlm.nih.gov/chemidplus/rn/987-65-5 https://www.hmdb.ca/metabolites/HMDB0000538 https://www.hmdb.ca/metabolites/HMDB0000538

IJT - CIR - February 2024

Table of Contents for the Digital Edition of IJT - CIR - February 2024

Contents
IJT - CIR - February 2024 - Cover1
IJT - CIR - February 2024 - Cover2
IJT - CIR - February 2024 - 1S
IJT - CIR - February 2024 - 2S
IJT - CIR - February 2024 - Contents
IJT - CIR - February 2024 - 4S
IJT - CIR - February 2024 - 5S
IJT - CIR - February 2024 - 6S
IJT - CIR - February 2024 - 7S
IJT - CIR - February 2024 - 8S
IJT - CIR - February 2024 - 9S
IJT - CIR - February 2024 - 10S
IJT - CIR - February 2024 - 11S
IJT - CIR - February 2024 - 12S
IJT - CIR - February 2024 - 13S
IJT - CIR - February 2024 - 14S
IJT - CIR - February 2024 - 15S
IJT - CIR - February 2024 - 16S
IJT - CIR - February 2024 - 17S
IJT - CIR - February 2024 - 18S
IJT - CIR - February 2024 - 19S
IJT - CIR - February 2024 - 20S
IJT - CIR - February 2024 - 21S
IJT - CIR - February 2024 - 22S
IJT - CIR - February 2024 - 23S
IJT - CIR - February 2024 - 24S
IJT - CIR - February 2024 - 25S
IJT - CIR - February 2024 - 26S
IJT - CIR - February 2024 - 27S
IJT - CIR - February 2024 - 28S
IJT - CIR - February 2024 - 29S
IJT - CIR - February 2024 - 30S
IJT - CIR - February 2024 - 31S
IJT - CIR - February 2024 - 32S
IJT - CIR - February 2024 - 33S
IJT - CIR - February 2024 - 34S
IJT - CIR - February 2024 - 35S
IJT - CIR - February 2024 - 36S
IJT - CIR - February 2024 - 37S
IJT - CIR - February 2024 - 38S
IJT - CIR - February 2024 - 39S
IJT - CIR - February 2024 - 40S
IJT - CIR - February 2024 - 41S
IJT - CIR - February 2024 - 42S
IJT - CIR - February 2024 - 43S
IJT - CIR - February 2024 - 44S
IJT - CIR - February 2024 - 45S
IJT - CIR - February 2024 - 46S
IJT - CIR - February 2024 - 47S
IJT - CIR - February 2024 - 48S
IJT - CIR - February 2024 - 49S
IJT - CIR - February 2024 - 50S
IJT - CIR - February 2024 - 51S
IJT - CIR - February 2024 - 52S
IJT - CIR - February 2024 - 53S
IJT - CIR - February 2024 - 54S
IJT - CIR - February 2024 - 55S
IJT - CIR - February 2024 - 56S
IJT - CIR - February 2024 - 57S
IJT - CIR - February 2024 - 58S
IJT - CIR - February 2024 - 59S
IJT - CIR - February 2024 - 60S
IJT - CIR - February 2024 - 61S
IJT - CIR - February 2024 - 62S
IJT - CIR - February 2024 - 63S
IJT - CIR - February 2024 - 64S
IJT - CIR - February 2024 - 65S
IJT - CIR - February 2024 - 66S
IJT - CIR - February 2024 - 67S
IJT - CIR - February 2024 - 68S
IJT - CIR - February 2024 - 69S
IJT - CIR - February 2024 - 70S
IJT - CIR - February 2024 - 71S
IJT - CIR - February 2024 - 72S
IJT - CIR - February 2024 - 73S
IJT - CIR - February 2024 - 74S
IJT - CIR - February 2024 - 75S
IJT - CIR - February 2024 - 76S
IJT - CIR - February 2024 - 77S
IJT - CIR - February 2024 - 78S
IJT - CIR - February 2024 - 79S
IJT - CIR - February 2024 - 80S
IJT - CIR - February 2024 - 81S
IJT - CIR - February 2024 - 82S
IJT - CIR - February 2024 - 83S
IJT - CIR - February 2024 - 84S
IJT - CIR - February 2024 - 85S
IJT - CIR - February 2024 - 86S
IJT - CIR - February 2024 - 87S
IJT - CIR - February 2024 - 88S
IJT - CIR - February 2024 - 89S
IJT - CIR - February 2024 - 90S
IJT - CIR - February 2024 - 91S
IJT - CIR - February 2024 - 92S
IJT - CIR - February 2024 - 93S
IJT - CIR - February 2024 - 94S
IJT - CIR - February 2024 - 95S
IJT - CIR - February 2024 - 96S
IJT - CIR - February 2024 - 97S
IJT - CIR - February 2024 - 98S
IJT - CIR - February 2024 - 99S
IJT - CIR - February 2024 - 100S
IJT - CIR - February 2024 - 101S
IJT - CIR - February 2024 - 102S
IJT - CIR - February 2024 - 103S
IJT - CIR - February 2024 - 104S
IJT - CIR - February 2024 - 105S
IJT - CIR - February 2024 - 106S
IJT - CIR - February 2024 - 107S
IJT - CIR - February 2024 - 108S
IJT - CIR - February 2024 - 109S
IJT - CIR - February 2024 - 110S
IJT - CIR - February 2024 - 111S
IJT - CIR - February 2024 - 112S
IJT - CIR - February 2024 - 113S
IJT - CIR - February 2024 - 114S
IJT - CIR - February 2024 - 115S
IJT - CIR - February 2024 - 116S
IJT - CIR - February 2024 - 117S
IJT - CIR - February 2024 - 118S
IJT - CIR - February 2024 - Cover3
IJT - CIR - February 2024 - Cover4
https://www.nxtbookmedia.com